Immunology and Neurology Flashcards
Corticosteroids (immunology)
MOA and Adverse effects
Binds with intracytoplasmic GC recepotr -> receptor complex is translocated to cell nucleus -> binds DNA GC response elements that affect gene transcription
GI ulceration, iatrogenic hyperadrenocorticism/adrenal gland suppression
Insulin resistance + secondary diabetes mellitus
Hypercoagulability
Muscle catabolism
Delayed wound healing
Opportunistic infections
Behavior changes
PU/PD, polyphagia, weight gain
Increased panting
Elevations of ALP activity (induction of steroid-induced isoenzyme)
Corticosteroids - effects on immune system
- Inhibits macrophage function (downregulates Fc receptor expression)
- Decreased antigen processing
- Decreased cell adhesion
- Suppression of T cell function
- T cell apoptosis
- Suppression of antibody production
Azathioprine
MOA: Thiopurine analog - disrupts DNA/RNA synthesis
Effects: decreased lymphocyte number + T-cell dependent Ab production
AE: GI disturbances, myelosuppression, hepatotoxicity, pancreatitis, secondary infection
Cyclosporin
MOA: Calcineurin inhibitor -> suppresses cytokine transcription
Effects: decreases T-cell proliferation + maturation (primarily T-helper cells)
AE: GI disturbances (freezing may help), gingival hyperplasia, secondary infection, alopecia, nephrotoxicity, hepatotoxicity, lymphoid neoplasia
Mycophenolate mofetil
MOA: purine syntehsis inhibitor - inhibits de novo guanine synthesis + disrupts DNA formation (inhibition of inosine-5’-monophosphate dehydrogenase [IMPDH])
Effects: Inhibits B-cells and T-cells, T-cell apoptosis, suppression of dendritic cell + monocyte activities
AE: Diarrhea/anorexia, myelosuppression, secondary infection, pancreatitis, allergic reaction (IV)
Mycophenolate metabolism in cats?
May be a problem because of their lack of glucuronidation
Chlorambucil
MOA: Alkylating agent - cell-cycle nonspecific; Prevents DNA synthesis through cross-linking DNA strands
Indications: Feline small cell GI lymphoma, chronic enteropathy, PRCA, pemphigus, ITP (cats), ICGN (dogs)
AE: GI upset, myelosuppression, neurotoxicity (cats), Fanconi syndrome (cats)
Leflunomide
MOA: Pyrimidine synthesis inhibitor - disrupts DNA synthesis
Effects: inhibits B-cells and T-cells
AE: Lethargy, GI upset, myelosuppression
Vincristine
MOA: Prevents assembly of microtubules - stimulates megakaryocyte fragmentation + may inhibit macrophage function
AE: GI upset, peripheral neuropathy, perivascular sloughing due to extravasation
Human IVIG
MOA: Consists of 90% purified human IgG (+trace IgM, IgA, CD4, CD8, HLA)
Effects: regulation of the immune system, inhibition of phagocytosis and reduction in tissue damage
1. Fc receptor blockade
2. Autoantibody elimination
3. Cytokine modulation
4. Complement inhibition
5. Fas-Fas ligand blockade
AE: Hypotension, hypersensitivity/anaphylaxis, thrombosis, AKI
Phenobarbital
MOA: y-aminobutyric acid (GAbA)-ergic activity by prolonging the opening of the chloride channel associated with the GABAa receptor. Inhibit glutamate receptors and voltage =-gated calcium channels
AE: Loading: extreme sedation, hypoventilation and/or hypotension
Hepatotoxicity (above 40mcg/mL), sedation, ataxia/CP deficits, PU/PD, polyphagia, excitation, bone marrow suppression, superficial necrolytic dermatitis, lowers thyroid levels, positive cPLI
Bromide (K/Na)
MOA: Halide anticonvulsant. Hyperpolarization of the neuron via movement of Br ions intracellularly through Cl channels
AE: Do not use in cats- fatal pneumonitis 35-42%
Transient GI disturbances with rectal administration
Neurologic deficits (sedation, agitation/excitability, caudal paresis, ataxia, decreased pelvic limb flexor withdrawals), polyphagia, PU/PD, vomiting, pancreatitis, gastric irritation, hyperchloremia (artifact)
Zonisamide
MOA: Sulfonamide drug. Inhibition of voltage-gated Na channels, inhibition of T-type Ca channels, modulation of dopaminergic activity, enhancement of GABA activity in the CNS, inhibition of carbonic anhydrase activity
AE: Ataxia, sedation, GI signs (vomiting, anorexia), KCS, decreased TT4, reported idiosyncratic hepatopathy in dogs
Levetiracetam
MOA: binding to synaptic vesicle protein SV2A -> decrease release of NT into the synapse
AE: Uncommon / usually mild
Sedation, salivation, vomiting (1200mg/kg/day)
Ataxia, stiff gait (300mg/kg/day)
Benzodiazepines
MOA: Facilitation of GABA-mediated inhibition and increased intracellular Cl flux
AE: Sedation, ataxia, weakness, hyperactivity, idiosyncratic hepatopthy in cats with PO diazepam